Vimarsana
Biggest News Aggregation in the World

Page 5 - Lars Wegner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lars Wegner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lars Wegner Today - Breaking & Trending Today

Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors - Vimarsana News

Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors

Share: COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma. The open label, multi-center study will assess the safety, tolerability, pharmacodynamic response and efficacy of EVX-02 with checkpoint inhibitors in patients who have had a complete resection of Stage IIIB/IIIC/IIID or Stage IV melanoma and ar...

Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in ... - Vimarsana News

Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in ... Evaxion BiotechDecember 23, 2020 GMT COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma. The open label, multi-c...

Source: apnews.com
Evaxion Biotech Appoints Marianne Søgaard as Chairwoman - Vimarsana News

Evaxion Biotech Appoints Marianne Søgaard as Chairwoman

Share: COPENHAGEN, Denmark, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S, a clinical-stage biotechnology company developing AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the appointment of previously practicing commercial, technology and corporate lawyer Marianne Søgaard as Chairwoman of the Board of Directors. Marianne Søgaard has been an executive and most recently Senior Vice President and General Counsel at Evaxion since 2018. Prior to that, she served for 22 years as lawyer and partner of the law firm Poul Sch...